A newer class of non-hormonal hot flash drugs may also ease the poor sleep that often comes with menopause, according to Contemporary OB/GYN's report of a meta-analysis presented at The Menopause Society 2026 Annual Meeting.
This article is based on that report. The study itself was not reviewed. The drugs are called neurokinin (NK) receptor antagonists. They block signals in the brain's NK pathways. Some drugs block both NK1 and NK3 receptors. Others block NK3 alone.
According to the report, the researchers pooled phase 2 and phase 3 randomized trials. The trials enrolled peri- and postmenopausal women with moderate-to-severe hot flashes. Sleep was measured with a patient-reported questionnaire, the PROMIS Sleep Disturbance Short Form 8b. The report does not say how many trials or participants were included.
At 4 weeks, women taking these drugs had lower sleep-disturbance scores than women on placebo. The report gives a pooled mean difference of −3.94 (95% confidence interval, −5.77 to −2.11). Dual NK1/NK3 drugs showed a larger difference (−5.24) than NK3-only drugs (−1.98). The report calls the gap between the two groups statistically significant.
The pattern held at 12 weeks. The overall difference was −3.15. Dual drugs came in at −4.52 and NK3-only drugs at −1.44. Again, the report says the gap between drug types was significant.
At 24 weeks, the overall difference was −2.04, with a wide confidence interval of −3.93 to −0.15. That is a smaller number than at 4 and 12 weeks, and the range of plausible values runs close to zero. The report does not give a breakdown by drug type at 24 weeks.
The authors, Lemos, Lopes de Mattos and Kaunitz, said the findings support a clinically meaningful role for NK pathway modulation in menopause-related sleep disturbance, according to the report. That is their interpretation.
Several questions remain open. The report does not say whether better sleep came from fewer night-time hot flashes or from another effect. It does not say how large a score change women would notice in daily life. It also does not describe side effects or how the individual trials were designed.
Watch for the full published paper, which should show the number of trials, the participants and how the drug groups compare at 24 weeks.
Anyone considering starting or stopping a menopause treatment should talk to their own clinician first.
Source: Contemporary OB/GYN (The Menopause Society 2026 Annual Meeting)
Keep reading on this subject
Women’s midlife · Sleep & circadian rhythms